Payers, drugmakers face off over CAR T Medicare coverage

CMS is receiving contradictory recommendations in response to its request for comments about creating a national policy on Medicare payments for CAR T cancer therapies. Payers' and patient advocacy groups' comments urged CMS to institute a National Coverage Determination (NCD) while drugmakers opposed,

Read the full 434 word article

User Sign In